VACCITECH PLC

This clinical-stage biopharmaceutical company was responsible for the technology behind the Oxford AstraZeneca vaccine.

Vaccitech was founded in 2016 by Professor Sarah Gilbert and Professor Adrian Hill as a spin out from Oxford University’s Jenner Institute, one of the world’s most prestigious vaccine centres.

Last April the company raised $166.5 million in a Series B private financing, and $110.5 million on its debut on the New York’s NASDAQ.

The company’s proprietary platform comprises Chimpanzee Adenovirus modes make it an ideal tool for researchers, students, coaches and physiotherapists studying athletes’ movement in their natural environments. In March, Vicon released an app update to offer an accessible and practical way to learn about inertial measurement units. This helps school and university students develop on the theory-based applied learning model as they will learn using the sensors by applying them to human movements.

Oxford (ChAdOx) and Modified Vaccinia Ankara (MVA), two nonreplicating viral vectors which safely mimic viral infection in human cells and elicit high magnitude, durable, targeted CD8+ and CD4+ T cell responses and antibodies to clear foreign pathogens and tumours. The company is set move into a new 31,000 sq ft headquarters and laboratory at Harwell Campus in Oxfordshire.